Senior Scientific Announces Issuance of U.S. Patent

Manhattan Scientifics Subsidiary Expands Patent Portfolio

May 23, 2013

Click here to view the printer friendly version of this press release

"Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."

Senior Scientific, LLC, a unit of Manhattan Scientifics and a developer of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the United States Patent Office (USPTO) has issued U.S. Patent No. 8,447,379 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."

 

The patent includes claims directed to detecting and measuring biological substances such as cancer cells. The methods can be used in humans, with no harmful radiation, and can find cancers much earlier than is possible with conventional technologies.

The technology is based on the work of Edward R. Flynn, PhD, in NanoMagnetic RelaxometryTM. The issued patent is further confirmation of the pioneering nature of Dr. Flynn’s work.

Gerald Grafe, president of Senior Scientific, said, "We are moving forward and making progress to bring Dr. Flynn’s technology to market, and this patent is an important addition to our intellectual property estate protecting the commercial value of the work."

Dr. Flynn, Chief Scientist of Senior Scientific, said, "I am encouraged to see my work heading to market, and pleased that we now also have this patent to protect the business."

Senior Scientific LLC, a unit of the company

About Manhattan Scientifics

Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.